GlassScriptPhysician profile
John M Feehery
NPI 1396826061
$2,112.05
in general payments reported to CMS, 2019-2025
18 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $31.98 · 2021: $255 · 2022: $245 · 2023: $426 · 2024: $329 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937 · Education: $75.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.80 |
| Education | $75.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $724.48 | 2019-2025 | Dupixent, Libtayo |
| Stryker Corporation | $438.13 | 2019-2025 | Scopis Ent, Xpress Loprofile |
| Glaxosmithkline, LLC. | $211.20 | 2022-2025 | Nucala |
| Intersect Ent, INC. | $195.13 | 2019-2022 | |
| Optinose US, INC. | $159.14 | 2019-2024 | |
| Neurent Medical Limited | $80.31 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark System, Neuromark Device |
| Alk-Abello, INC | $76.32 | 2019-2021 | |
| Acclarent, INC | $39.56 | 2019 | |
| Aerin Medical INC. | $37.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $25.00 | 2021 | |
| Smith+Nephew, INC. | $18.81 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $18.37 | 2024 | Exparel, Iovera |
| Paratek Pharmaceuticals, INC. | $17.46 | 2025 | Xhance |
| Phathom Pharmaceuticals, INC. | $14.94 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $14.66 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $14.34 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $13.78 | 2025 | Neffy |
| Glenmark Therapeutics INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Feehery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.